NCT01697527View on ClinicalTrials.gov

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 2, 2012

Primary Completion Date

November 2, 2025

Study Completion Date

November 2, 2026

Conditions
Malignant Neoplasm
Interventions
BIOLOGICAL

aldesleukin

Given SC

DRUG

fludarabine phosphate

Given IV

DRUG

cyclophosphamide

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL

Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL

BIOLOGICAL

dendritic cell vaccine therapy

Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID

RADIATION

fludeoxyglucose F 18

Undergo PET scan using \[18F\] FDG tracer

PROCEDURE

positron emission tomography

Undergo fludeoxyglucose F18 PET

Trial Locations (1)

90095

University of California at Los Angeles (UCLA ), Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER